RESUMEN
Background: Tuberculosis remains a global disease that poses a serious threat to human health, but there is lack of new and available anti-tuberculosis agents to prevent the emergence of drug-resistant strains. To address this problem natural products are still potential sources for the development of novel drugs. Methods: A whole-cell screening approach was utilized to obtain a natural compound enniatin A1 from a natural products library. The target compound's antibacterial activity against Mycobacterium tuberculosis (M. tuberculosis) was evaluated by using the resazurin reduction micro-plate assay (REMA) method. The cytotoxicity of the compound against Vero cells was measured to calculate the selectivity index. The intracellular inhibition activity of enniatin A1 was determined. We performed its time-kill kinetic assay against M. tuberculosis. We first tested its synergistic effect in combination with the first and second-line anti-tuberculosis drugs. Finally, we measured the membrane potential and intracellular ATP levels of M. tuberculosis after exposure to enniatin A1. Results: We identified enniatinA1 as a potential antibacterial agent against M. tuberculosis, against which it showed strong selectivity. Enniatin A1 exhibited a time-concentration-dependent bactericidal effect against M. tuberculosis, and it displayed synergy with rifamycin, amikacin, and ethambutol. After exposure to enniatinA1, the membrane potential and intracellular ATP levels of M. tuberculosis was significantly decreased. Conclusions: Enniatin A1 exhibits the positive potential anti-tuberculosis agent characteristics.
Asunto(s)
Adenosina Trifosfato/metabolismo , Antituberculosos/farmacología , Depsipéptidos/farmacología , Potenciales de la Membrana/efectos de los fármacos , Mycobacterium tuberculosis/metabolismo , Tuberculosis/tratamiento farmacológico , Animales , Antituberculosos/agonistas , Chlorocebus aethiops , Depsipéptidos/agonistas , Evaluación de Medicamentos , Sinergismo Farmacológico , Humanos , Células THP-1 , Células VeroRESUMEN
Tuberculosis (TB) is responsible for enormous global morbidity and mortality, and current treatment regimens rely on the use of drugs that have been in use for more than 40 years. Owing to widespread resistance to these therapies, new drugs are desperately needed to control the TB disease burden. Herein, we describe the rapid synthesis of analogues of the sansanmycin uridylpeptide natural products that represent promising new TB drug leads. The compounds exhibit potent and selective inhibition of Mycobacterium tuberculosis, the etiological agent of TB, both in vitro and intracellularly. The natural product analogues are nanomolar inhibitors of Mtb phospho-MurNAc-pentapeptide translocase, the enzyme responsible for the synthesis of lipid I in mycobacteria. This work lays the foundation for the development of uridylpeptide natural product analogues as new TB drug candidates that operate through the inhibition of peptidoglycan biosynthesis.
Asunto(s)
Antituberculosos/farmacología , Productos Biológicos/farmacología , Monosacáridos/biosíntesis , Oligopéptidos/biosíntesis , Oligopéptidos/farmacología , Uridina/análogos & derivados , Animales , Antituberculosos/agonistas , Antituberculosos/química , Productos Biológicos/agonistas , Productos Biológicos/química , Humanos , Ratones , Mycobacterium tuberculosis/efectos de los fármacos , Oligopéptidos/sangre , Oligopéptidos/química , Uridina/sangre , Uridina/química , Uridina/farmacologíaRESUMEN
The effects of oxidized dextrans of different molecular weight on reactive oxygen species production and transmembrane mitochondrial potential of macrophages and neutrophils have been studied in vivo and in vitro. Oxidised dextrans demonstrated moderate direct antioxidant ability but induced intracellular oxidative stress through the increase of oxygen radical generation. This effect of the investigated compounds amplifies the cytotoxic and bactericidal potential of phagocytes and can influence isoniazid metabolism, thus increasing its efficiency in therapy of infectious diseases.
Asunto(s)
Antioxidantes/farmacología , Dextranos/farmacología , Macrófagos Peritoneales/patología , Neutrófilos/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Animales , Antituberculosos/agonistas , Antituberculosos/farmacología , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/metabolismo , Dextranos/agonistas , Sinergismo Farmacológico , Femenino , Isoniazida/agonistas , Isoniazida/farmacología , Macrófagos Peritoneales/citología , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Ratones , Peso Molecular , Neutrófilos/citología , Oxidación-Reducción/efectos de los fármacos , Sustitutos del Plasma/farmacologíaRESUMEN
Isoniazid (INH) is an integral component of treatment of tuberculosis. An acute overdose is potentially fatal and is characterised by the clinical triad of repetitive seizures unresponsive to the usual anticonvulsants, metabolic acidosis with a high anion gap and coma. A case of isoniazid induced seizures after therapeutic dose of 600 mg. as a part of CAT I thrice weekly intermittent anti-tuberculosis regimen for pulmonary tuberculosis is reported. The frequency of the usage of Isoniazid as antituberculosis therapy requires that physicians be aware of such toxicity.